Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SCD-044 in Moderate to Severe Plaque Psoriasis
2023-506477-35-00Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of vibozilimod in plaque psoriasis (5 arms), sponsored by Sun Pharma. Primary endpoint: PASI75 response at Week 16. Started Feb 2024; status: completed.
02
Drugs
vibozilimod
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-506477-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506477-35-00.